Nymox Pharmaceutical Corporation (NYMXF)
USD 0.14
(-8.36%)
USD 0.14
(-8.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.33 Million USD | 25.59% |
| 2022 | 6.64 Million USD | -46.85% |
| 2021 | 12.49 Million USD | 6.66% |
| 2020 | 11.71 Million USD | -12.43% |
| 2019 | 13.37 Million USD | 23.85% |
| 2018 | 10.79 Million USD | -18.86% |
| 2017 | 13.3 Million USD | 2.55% |
| 2016 | 12.97 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q3 | 1.01 Million USD | -7.84% |
| 2023 Q4 | 4.85 Million USD | 379.72% |
| 2023 Q2 | 1.09 Million USD | -20.62% |
| 2023 Q1 | 1.38 Million USD | 182.46% |
| 2022 Q1 | 5.07 Million USD | 81.17% |
| 2022 Q2 | 1.77 Million USD | -65.1% |
| 2022 Q4 | -1.67 Million USD | -213.63% |
| 2022 FY | 6.64 Million USD | -46.85% |
| 2022 Q3 | 1.47 Million USD | -16.67% |
| 2021 Q4 | 2.79 Million USD | -14.95% |
| 2021 FY | 12.49 Million USD | 6.66% |
| 2021 Q3 | 3.29 Million USD | 0.0% |
| 2020 FY | 11.71 Million USD | -12.43% |
| 2019 FY | 13.37 Million USD | 23.85% |
| 2018 FY | 10.79 Million USD | -18.86% |
| 2017 FY | 13.3 Million USD | 2.55% |
| 2016 FY | 12.97 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -524.443% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -65.389% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 71.783% |
| Nascent Biotech, Inc. | 2.22 Million USD | -273.966% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1155.873% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 77.617% |
| Qrons Inc. | 643.67 Thousand USD | -1195.526% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2040.587% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 85.482% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1907.081% |
| Skye Bioscience, Inc. | 13.54 Million USD | 38.446% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 90.391% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -69.564% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3086.157% |
| SQZ Biotechnologies Company | 85.61 Million USD | 90.26% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -185.951% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -455.23% |
| Mesoblast Limited | 5.9 Million USD | -41.291% |
| Marizyme, Inc. | 19.23 Million USD | 56.658% |
| Genus plc | 147.7 Million USD | 94.354% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 5.014% |
| Pharming Group N.V. | 225.49 Million USD | 96.302% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -307.038% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -521.597% |
| ContraFect Corporation | 56.88 Million USD | 85.342% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -89.15% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -463.921% |
| IMV Inc. | 37.7 Million USD | 77.886% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -198.851% |
| MultiCell Technologies, Inc. | 567.42 USD | -1469534.486% |
| ONE Bio Corp. | 6.44 Million USD | -29.409% |
| Accustem Sciences Inc. | 3.74 Million USD | -122.586% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 90.297% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1467.593% |
| Q BioMed Inc. | 3.43 Million USD | -142.651% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 66.259% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -217.371% |
| Biomind Labs Inc. | 994.18 Thousand USD | -738.78% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 91.605% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -373.894% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -24.129% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -347.282% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 33456.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 47.915% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -354.418% |
| GB Sciences, Inc. | 1.42 Million USD | -487.043% |
| Alpha Cognition Inc. | 9.7 Million USD | 14.081% |
| HST Global, Inc. | 140.9 Thousand USD | -5818.088% |
| CSL Limited | 3.44 Billion USD | 99.758% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -641.304% |
| Halberd Corporation | 74.84 Thousand USD | -11042.139% |
| Enzolytics Inc. | 2.17 Million USD | -282.609% |
| Agentix Corp. | 1.37 Million USD | -507.907% |
| Resverlogix Corp. | 12.71 Million USD | 34.401% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -128.422% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.456% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -698.755% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -246.745% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -428.0% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -144.906% |
| AVAX Technologies, Inc. | 7.31 Million USD | -14.072% |
| Zenith Capital Corp. | 8.94 Million USD | 6.754% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.99% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -47767.516% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -239.63% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4762.136% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -334.118% |
| Kadimastem Ltd | 2.41 Million USD | -246.001% |
| Helix BioMedix, Inc. | 1.97 Million USD | -322.863% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 23.263% |
| BioStem Technologies, Inc. | 22.97 Million USD | 63.704% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4494.87% |
| LadRx Corporation | 3.81 Million USD | -118.769% |
| Cell Source, Inc. | 4.32 Million USD | -92.794% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -802.968% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -802.968% |
| NovAccess Global Inc. | 2.46 Million USD | -238.055% |
| Affymax, Inc. | 39.38 Million USD | 78.828% |
| Itoco Inc. | 919.14 Thousand USD | -807.258% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -96.748% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -645.219% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1403.753% |
| CytoDyn Inc. | 18.05 Million USD | 53.821% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -33032.027% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3689.111% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -487.34% |
| SYBLEU INC | 160.87 Thousand USD | -5083.495% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -359.115% |
| International Stem Cell Corporation | 5.27 Million USD | -58.205% |
| Bioxytran, Inc. | 3.82 Million USD | -118.29% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -15740.963% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -40891.987% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 77.006% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -415.389% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1033.27% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -168.049% |
| Neutra Corp. | 243.82 Thousand USD | -3320.132% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 52.231% |
| PureTech Health plc | 144.59 Million USD | 94.233% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 59.302% |
| IXICO plc | 4.7 Million USD | -77.162% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 5.206% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.918% |
| CSL Limited | 3.89 Billion USD | 99.786% |
| Cellectis S.A. | 97.32 Million USD | 91.431% |